Clearside Biomedical's axitinib injectable suspension phase 1/2a trial enrolls first patients

Article

Delivery into the suprachoroidal space may potentially extend the duration of therapeutic action and reduce or relieve the treatment burden for wet AMD.

Recent Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
This series features 1 KOL.
This series features 1 KOL.
This series features 1 KOL.
Video 2 - 1 KOL is featured in, "Advances in Technology for SMILE procedure"
Video 1 - 1 KOL is featured in, "Overview of Small Incision Lenticule Extraction (SMILE)"
Related Content
Ocugen completes dosing in subjects with GA secondary to dAMD in Phase 1/2 ArMaDa clinical trial of OCU410

Ocugen completes dosing in subjects with GA secondary to dAMD in Phase 1/2 ArMaDa clinical trial of OCU410

Article
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics

Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics

Podcast
Richard Rosen, MD, honored with distinguished award from ASRS

Richard Rosen, MD, honored with distinguished award from ASRS

Article
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics

Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention

Podcast
Researchers monitor eye microcirculation using multiwavelength laser Doppler holography in time-frequency optical tomography OCT

Researchers monitor eye microcirculation using multiwavelength laser Doppler holography in time-frequency optical tomography OCT

Article
Case Western Reserve University receives $1.5 million grant from Foundation Fighting Blindness to test possible new treatment for inherited retinal disease

Case Western Reserve University receives $1.5 million grant from Foundation Fighting Blindness to test possible new treatment for inherited retinal disease

Article
© 2024 MJH Life Sciences

All rights reserved.